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Measles Virus Infection in a Transgenic Model:
Virus-Induced Immunosuppression
and Central Nervous System Disease
acute sclerosing panencephalitis (SSPE) (ter Meulen et
al., 1983; Griffin and Bellini, 1996). Despite much work
in this area, precisely how MV enters cells, disorders
the immune system, and spreads in the CNS to cause
disease is largely unclear. Without a suitable small ani-
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mal model in which one can dissect and define theseDepartment of Neuropharmacology
phenomena at the molecular level, such questions re-The Scripps Research Institute
main unanswered.10550 North Torrey Pines Road
With the recent knowledge that human CD46 moleculeLa Jolla, California 92037
and any one of its four major isoforms serve as a receptor²Department of Cell Biology
for MV (Dorig et al., 1993; Naniche et al., 1993; Manches-Rockefeller University
ter et al., 1994), attention has been directed to generat-New York, New York 10024
ing transgenic mice with this component (Horvat et al.,
1997; Rall et al., 1997; Thorley et al., 1997; Blixenkrone-
Moller et al., 1998; Mrkic et al., 1998). Rodents lack the
Summary CD46 molecule and are generally nonpermissive to MV
infection (Dorig et al., 1993; Naniche et al., 1993; Man-
Measles virus (MV) infects 40 million persons and kills chester et al., 1994; Horvat et al., 1997; Rall et al., 1997;
one million per year primarily by suppressing the im- Thorley et al., 1997; Mrkic et al., 1998) unless the virus
mune system and afflicting the central nervous system undergoes multiple blind passages through mouse brain
(CNS). The lack of a suitable small animal model has cells (Liebert and Finke, 1995). Such rodent-passaged
impeded progress of understanding how MV causes MVs are phylogenetically distant from other MV isolates
disease and the development of novel therapies and and are tropic only for the CNS (Liebert and Finke, 1995;
improved vaccines. We tested a transgenic mouse line Rima et al., 1995). However, insertion and expression
in which expression of the MV receptor CD46 closely of CD46 in rodent cells convert them from a state of
mimicked the location and amount of CD46 found in resistence to permissivity for MV infection after a single
humans. Virus replicated in and was recovered from passage (Dorig et al., 1993; Naniche et al., 1993; Man-
chester et al., 1994). Unfortunately the CD46 transgenicthese animals' immune systems and was associated
models generated so far have been limited either bywith suppression of humoral and cellular immune re-
negligible expression in one of the two sites needed forsponses. Infectious virus was recovered from the CNS,
study of MV pathogenesis, the CNS and immune systemreplicated primarily in neurons, and spread to distal
(Rall et al., 1997; Blixenkrone-Moller et al., 1998), as wellsites presumably by fast axonal transport. Thus, a small
as a failure to generate a substantial MV infection in vivoanimal model is available for analysis of MV patho-
(Horvat et al., 1997; Thorley et al., 1997; Mrkic et al., 1998)genesis.
or specificity for MV (Blixenkrone-Moller et al., 1998).
We sought to utilize a CD46 transgenic mouse model
Introduction without these limitations. A yeast artificial chromosome
(YAC) library was used to obtain a full-length CD46 geno-
Measles virus (MV) is among the most contagious agents mic clone; the YAC flanking sequence was removed,
of infection in humans (Griffin and Bellini, 1996; Old- after which the entire CD46 gene was microinjected
stone, 1998). Despite the development and use of an into fertilized mouse eggs (Yannoutsos et al., 1996). The
excellent vaccine, over 40 million persons become in- resulting transgenic mice expressed all four major iso-
fected, and over one million die each year (Markowitz forms of CD46: BC1, BC2, C1, and C2. We noted that
and Katz, 1994; Griffin and Bellini, 1996; Oldstone, 1998). the locations and amounts of CD46 mimicked that in
MV typically infects both the immune system and central humans (Liszewski et al., 1991; Russell et al., 1992), and
nervous system (CNS) (McChesney and Oldstone, 1989; overall expression was greater than previously reported
Markowitz and Katz, 1994; Griffin and Bellini, 1996). MV for the other transgenic models (Horvat et al., 1997; Rall
causes a profound suppression of the immune system et al., 1997; Thorley et al., 1997; Blixenkrone-Moller et
(McChesney and Oldstone, 1989; Markowitz and Katz, al., 1998; Mrkic et al., 1998).
1994; Griffin and Bellini, 1996), which, when in associa- Following intracerebral (i.c.) inoculation of newborn
tion with secondary infections, is the major cause for mice and intraperitoneal (i.p.) or intraveneous (i.v.) inoc-
the high morbidity and mortality. In addition, the virus ulation of adult mice, MV replicated in cells of the im-
can produce encephalomyelitis during its acute phase mune system and CNS and infectious virus were re-
of infection and uncommonly cause postinfectious hy- coverable from both by cocultivation on Vero cells.
Virus was found primarily in T-enriched areas of theperallergic encephalomyelitis, subacute encephalitis, and
spleen and circulating PBL, and CD8, CD4 T cells, Bpersistent infection of neurons, a disease called sub-
cells, and macrophages were able to release virus. Fur-
ther, the immune system's function was suppressed. In
the CNS, MV replicated primarily in neurons, then spread³ To whom correspondence should be addressed (e-mail: mbaobo@
scripps.edu). rapidly throughout the nervous system. T lymphocyte
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infiltration and apoptosis of neurons were associated
with death usually by 21 days after infection. As such,
this model reproduces multiple aspects of MV infection
in humans.
Results
Generation of Transgenic Mice and Expression
of CD46 RNA and Protein
CD46-expressing transgenic mice (Yannoutsos et al.,
1996) YAC CD46 line 2 (YAC-CD46) contained 10 to 12
genome copies of CD46 and expressed all four of its
major isoforms (Liszewski et al., 1991; Yannoutsos et
al., 1996). After documenting integration and perpetua-
tion of the CD46 gene for two generations, we deter-
mined the expression of CD46 RNA and protein of these
mice using in situ hybridization within whole-animal sec-
tions and in Northern blots. Expression of CD46 tran-
scripts and proteins detected within whole-animal sec-
tions (Figures 1A and 1B) was ubiquitous in YAC-CD46
transgenic mice but absent in the nontransgenic mice
(6 of 6 mice studied in each group). When 4 mg RNA
extracted separately from brain, spleen, lymph nodes,
thymus, kidney, liver, gut, and lung was blotted on nitro-
cellulose and hybridized with a 32P-labeled CD46 cDNA
probe, Northern blot analysis revealed that these tissues
from transgenic mice expressed the 4.5 to 4.8 kb CD46
transcript. By contrast, the same amount of RNA from
nontransgenic mice did not contain any CD46 tran-
scripts (3 of 3 mice studied in each group). In another
transgenic line, neuron-specific enolase (NSE)-CD46,
CD46 RNA was restricted to the brain (Rall et al., 1997),
but we could not detect any CD46 transcripts or proteins
in whole-animal sections of these mice. Even in brains
of four NSE-CD46 transgenic mice, no 32P-labeled CD46
was evident, although by RT±PCR CD46 was readily
detected (data not shown; Rall et al., 1997), implying
that the endogenous CD46 promoter more efficiently
expressed CD46 than the NSE promoter. To compare
the CD46 protein expression in brains of these two dis-
tinct transgenic lines, we quantitated CD46 protein on
the surface of hippocampal neurons derived from either
YAC-CD46 mice or NSE-CD46 mice. Neurons from YAC-
CD46 mice contained at least 10-fold more CD46 mole-
cules than neurons from NSE-CD46 mice. Data from two
additional experiments showed that the concentration
of CD46 in YAC-CD46 mice was 10- to 20-fold higher
than in NSE-CD46 mice. Therefore, YAC-CD46 mice
were used for the remainder of these studies.
Staph A (see Experimental Procedures). MV (103 pfu) was given i.c.
to newborn mice (A), and i.v. or i.p. to 65-day-old adult mice. Since
results from i.p. and i.v. inoculations were similar, only the latter
data are shown. Whole body in situ assay of control (normal, non-
transgenic) mice showed no evidence of CD46 transcripts or protein,
Figure 1. YAC-CD46 Mice Express CD46 Molecules in Multiple both of which are abundantly expressed throughout YAC-CD46 tg1
Tissues mice. This profile for expression or absence of expression for CD46
Thirty micron whole-animal sections were made from (A) 10-day- transcripts and protein was identical for an additional two non-
old and (B) 65-day-old nontransgenic (tg2) and YAC-CD46 transgenic transgenic and three YAC-CD46 mice. Background 32P in control
(tg1) mouse. CD46 RNA was detected using a 32P-labeled ribo- mice represents binding of probe to hydroxylapatite in bone (Old-
probe and CD46 protein with an antibody to CD46 and 125I-labeled stone et al., 1986; Lipkin et al., 1989).
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Figure 2. Expression of CD46 Molecules and Infectibility of Cells Harvested from YAC-CD46 Transgenic Mice
Upper left panel shows expression of CD46 protein on CD4 and CD8 lymphocytes obtained and sorted by FACS. Cells were stained with
antibody to CD4 and cy-chromeE dye, antibody to CD8 and allophycocyanin, and antibody to CD46 conjugated to FITC. Antibodies to B cells
and phycoerythrin were used to remove B cells. Positive controls appear as shown. Upper right panel shows CD46 on YAC-CD46 red blood
cells (clear area) compared to their non-YAC-CD46 transgenic counterparts (shaded area). Lower panel shows expression of MV proteins in
peritoneal macrophages (left), kidney cells (center), and skin fibroblasts (right) obtained from CD46 transgenic mice and infected in vitro with
MV at MOI of 3. FITC-labeled antibody specific for MV identifies MV antigens. Non-MV-infected cells did not stain with these reagents. Viral
progeny were found in supernatants after plaquing on permissive Vero cells. Titers of MV rarely exceeded 3 logs of virus/ml. Corresponding
cells from tissues of nontransgenic mice were not infectible by MV. Monoclonal antibody E4.3 was used to stain CD46 on surfaces of cells
and polyclonal antibody specific for MV to detect MV antigens (see Experimental Procedures).
Multiple Cell Types from YAC-CD46 Mice Express cervical, mesenteric, and peribronchial lymph nodes; in
the spleen (Figures 3B±3D); in Peyer's patches; and inCD46 Proteins and Are Infectible In Vitro by MV
Cells from the kidneys, skin, neurons, macrophages, peribronchial endothelial cells (5 of 5 mice studied).
In spleens and lymph nodes, MV was expressed pre-and dendritic cells, as well as B lymphocytes, CD81,
and CD41 T lymphocytes of YAC-CD46 mice expressed dominantly in T cell±enriched areas (Figure 3D).
We utilized double-labeling procedures to identifyCD46 molecules on their surfaces (5 of 5 mice studied).
These cells became infected with MV, expressed MV unique cells in the spleen and brain that expressed MV
RNA and/or antigens (Figure 4) and cocultivation tech-antigens, and released infectious viral progeny when
cocultivated with permissive Vero cells (Figure 2). Cul- niques to isolate infectious virus that was then quanti-
tated (Figures 3 and 4). MV RNA was detected with atured skin and kidney cells, macrophages, as well as
lymphocytes that had been activated by mitogens or digoxigenin riboprobe and MV proteins by immunocyto-
chemistry or Western blots using a human antibody toplaced in mixed lymphocyte cultures produced low titers
of infectious virus (102 to 103 pfu/ml) that were recover- MV. To mark individual splenic cells, we used directly
conjugated (FITC, PE) monoclonal antibodies to CD4able from the supernatant fluids. However, no released
virus was detected in supernatants from cultured neu- (L3T4, RM4-5), to CD8 (Ly-2, 53±6.7), to B cells (B220,
CD45B), and to macrophages (MAC-1, CD11b) with fluo-rons, although infectious virus was formed upon coculti-
vation with Vero cells. Interestingly, and different from rescence-activated cell sorter (FACS). To mark individ-
ual CNS cell populations, we employed monoclonal orCD46 expression in humans (Liszewski et al., 1991), red
blood cells from YAC-CD46 mice also expressed CD46 monospecific rodent antibodies reactive with neurons
(antibody to MAP-2), oligodendrocytes (antibody tomolecules on their surfaces as detected in a hemaggluti-
nin assay and by reaction with anti-CD46 monoclonal MBP), astrocytes (antibody to GFAP), and microglia (an-
tibody to F4/80). Five to six days after i.c. inocula-antibodies (Figure 2).
tion of MV into newborns, at least five spleens were
harvested from YAC-CD46 mice and separated intoMV Infects Neurons and Lymphoid Cells in the Blood,
Spleen, and Lymph Nodes of YAC-CD46 Mice lymphocyte and macrophage populations or into a
lymphoid-enriched splenic population. FACS insuredAfter 103 pfu of MV was injected i.c. into neonates, and
i.v. or i.p. into adult YAC-CD46 mice, MV RNA and pro- that purity of cell subsets studied exceeded 99%, and
by staining 6 of 1400 CD41 T cells (0.4%), 15 of 1500tein were expressed in the CNS (Figures 1 and 3A); in
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10±12 days the presence of similar syncytia in both CD41
T lymphocyte and macrophage cultures was usually ob-
served. Infectious virus was recovered by day 9 or later,
and at day 14 over 105 pfu of virus per milliliter of culture
supernatant was recorded from spleen, CD81 T, and
CD41 T cell cultures. Isolation of MV from whole spleen
or lymphoid subsets was noted 4±7 days after i.c. inocu-
lation of newborn (ten mice) YAC-CD46 transgenic mice.
Analysis of brain at similar harvested periods indicated
recovery of two logs more infectious virus at day 9 than
from the spleen (Figure 3). Immunochemical analysis indi-
cated that MV expression was restricted almost entirely
to neurons (Figure 4; .99% of 1000 cells counted) and
was occasionally present in oligodendrocytes (,0.01%)
and microglia (,0.5%). MV antigen was absent from
GFAP1 cells. Attempts to recover virus in the absence
of cocultivation failed.
MV Initiates CNS Disease in YAC-CD46 Mice
After i.c. inoculation of 103 or more pfu of MV, viral
transcripts and antigens were detected in groups of
neurons throughout the recipient's CNS. As shown in
Figure 4A (lanes 1 and 2) and Figure 4C, viral RNA was
expressed in the brain 6 days after infection of newborn
YAC-CD46 transgenic mice. From Figure 4C, it is evident
that MV RNA was present in multiple sites of the brain.
No MV transcripts were detected in brains of non-CD46
mice inoculated with equivalent doses of virus (Figure
4A, lanes 3±5 and 4B). Higher resolution light micros-
copy demonstrated that MV antigens resided in neurons
Figure 3. Expression of MV Antigens in Brain, Lymph Nodes, and throughout the optic tegmentum (D), cerebral cortex
Spleen of a 6-Day-Old YAC-CD46 Mouse and Recovery of Infectious (E, G±I), hippocampus (J), and cerebellum (K). Electron
MV from a Pool of Five 6-Day-Old mice Inoculated at Birth Intracere-
microscopy revealed abundant MV nucleocapsids in in-brally with 103 pfu of MV
fected neurons (Figure 5). Further, MV nucleocapsidsWhole animal sections of 10 mm were fixed and stained with anti-
appeared to move into neuritic processes (axons) con-body to MV in a peroxidase reaction assay (see Experimental Proce-
taining normal and disorganized microtubules (Figuresdures for details). Inserts represent tissues from this mouse shown
at higher magnifications. 5A, 5B, 5E±5G). Infectious MV was recovered from
(A) Brain at 2003 magnification with the brown-colored cells con- brains after cocultivation with Vero cells (Figures 3 and
taining MV antigens. At higher magnification or after double staining 4F). Accompanying MV replication and spread was a
with cell-specific probes, cells were identified as neurons (see Fig-
generalized astrocytosis (Figure 4L), activation of micro-ures 4±6).
glia, and infiltration primarily of CD41 T cells (M) and(B) Cervical lymph node. Magnification, 4003.
some CD81 T cells (N) into the brain parenchyma. FVB/(C) Peribronchial lymph node. Magnification, 4003.
(D) Spleen (magnification, 2003) with MV antigen in lymphocytes N (H-2q) mice were subject to these sequela of MV infec-
around central vessel. Similar results were obtained from three addi- tion; over 94% died within 3 weeks postinfection after
tional YAC-CD46 mice. Three similarly aged non-YAC-CD46 mice displaying lethargy, weakness, occasional paraplegia,
inoculated with MV failed to display immunochemical staining of
and seizures. Expression of MV transcripts or proteinany tissues when the same reagents were employed.
was observed in 20 out of 20 CD461 transgenic mice.Lower table indicates day of recovery and amounts of infectious
By contrast, 10 out of 10 non-CD461 transgenics failedMV obtained from spleen and brain after cocultivation with Vero
cells. Similar results occurred on two separate experiments. Infec- to display MV transcripts or proteins or replicate MV
tious virus was not recovered from MV-inoculated non-CD46 tg after similar virus inoculation. A similar degree and tim-
mice. ing of mortality uniformly followed MV infection in other
strains of CD46 transgenic mice crossed to the F2 level,
including BALB (H-2d), SWR/J (H-2q), SJL (H-2s), PLJCD81 T cells (1.0%), 3 of 3369 B cells (0.09%), and 2
of 510 MAC-11 monocytes/macrophages (0.4%) ex- (H-2u), C3H (H-2k), and C57BL/6 (H-2b) mice crossed to
the C57BL/6 background to seven generations. Yet,pressed MV gene products. By contrast, analysis of
similar cell populations from non-YAC-CD46 mice in- none of the sex- and strain-matched nontransgenic lit-
termates became ill following MV inoculation (i.c., 103fected with MV failed to express MV gene products.
FACS-purified populations of CD81, CD41 T, and B lym- to 105 pfu) or expressed MV transcripts or proteins (three
to eight mice per group).phocytes; macrophages; and whole spleen lymphoid
cells were placed in culture with Vero cells. After 6 but Activation of astrocytes and microglia along with infil-
tration of T lymphocytes after MV infection suggestedusually 8±10 days, small but definitive syncytia began
to form in cultures containing CD81 T lymphocytes, B that cytokines and/or chemokines were being synthe-
sized in the CNS. To evaluate this possibility, both totallymphocytes, and whole splenic lymphoid cells. After
Novel Small Animal Model to Dissect MV Pathogenesis
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Figure 4. Specificity and Expression of MV in the CNS after Infection of YAC-CD46 Transgenic Mice
MV RNA ([A], lanes 1 and 2 and [C]) and protein (D, E, G±K) were expressed in neurons throughout the brains of infected YAC-CD46 mice.
MV was isolated when brain tissue components were cocultivated on Vero cells. Insert shows staining of a syncytia located in Vero cells with
monoclonal antibody to MV (F) (see Experimental Procedures). No MV RNA was detected in nontransgenic mice given a similar inoculum of
MV ([A], lanes 3±5 and [B]). Infection was accompanied by generalized activation of astrocytes ([L] antibody to GFAP), brisk CD41 T cell (M)
and modest CD81 T cell infiltration (N). Newborn YAC-CD46 mice were inoculated i.c. with 103 pfu of MV; their brains were harvested 6 to 10
days later as a source of isolated RNA or tissue fixed in 2% paraformaldehyde, sectioned on a vibratome, and stained for expression of MV
RNA or antigens as described in Experimental Procedures. (A) shows MV transcripts in brains from two CD461 transgenic mice (lanes 1 and
2) but not from two nontransgenic littermates (lanes 3 and 4) or from a normal mouse (lane 5) infected with 105 pfu of MV. Hybridization was
with a MV probe in which the viral N was deleted (see Experimental Procedures). In (B) no MV transcripts appear in a nontransgenic mouse
tested by in situ hybridization, whereas (C) shows the presence of MV transcripts. For (B) and (C), MV N probe was used. Expression of MV
antigens is observed in (D) optic tigmentum; (E, G±I) separate areas in the cerebral cortex; (J) hippocampus; (K) Purkinje neuron in the
cerebellum. Results were similar in brains from three other MV-infected YAC-CD46 mice inoculated with 103 pfu and in groups of three mice
inoculated with either 104 or 105 pfu of MV. (L) shows activated astrocytes near the hippocampal area as revealed by GFAP stain. Corresponding
astrocytosis was found in areas throughout the CNS. (M) and (N) display infiltrating CD41 and CD81 T lymphocytes, respectively, in an area
by the cerebellum. Tissue sections were 5 mm apart. A similar preponderance of CD41 T cells occupied the cerebral cortex. (P) shows
apoptosis of neurons found in MV-infected YAC-CD46 mice. By contrast, inoculation of MV into nontransgenic littermates did not produce
MV replication (A and C) and did not show presence of MV antigens in neurons (data not shown), T cell infiltration, or astrocytosis, and
apoptosis was negligible (O).
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Figure 5. Selected Examples Illustrate Virus
Nucleocapsids within Neurons
(A) The arrows point to a neurite emerging
from a neuron in which the nucleus (N) is pyc-
notic.
(B) A region of this neurite shown at a higher
magnification to demonstrate nucleocapsids
(arrow) and microtubules indicated by short
arrows.
(C) Illustrates massive accumulations of nu-
cleocapsids (arrows) in the cytosol of a
neuron.
(D) Selected region of (C) at a higher resolu-
tion demonstrates the helical configuration
(arrows) of individual nucleocapsids.
(E) Section through a neurite illustrates pres-
ence of microtubules (short arrows) and nu-
cleocapsids (arrows).
(F) Portion of the nucleus (N) and cytoplasm
including a mitochondrion (M) of a neuron
contiguous to a neurite process indicated by
arrows, in which nucleocapsids are evident.
(G) The same process shown at a higher reso-
lution contains microtubules (short arrows)
and numerous nucleocapsids. The length of
magnification bars is as follows: (A and F) 1.0
mm; (B, C, E, and G) 0.5 mm; (D) 0.25 mm.
RNA and poly(A)-enriched RNA were isolated from 4O). Apoptotic cells were identified as being primary
neurons by double labeling. CC chemokines, such asbrains of MV-infected and uninfected YAC-CD46 mice
(103 and 105 pfu, four mice per group). By RPA, when Rantes, MIPa and b, and MCP-1, or CXC chemokines,
such as IP-10 and TCA-3, which attract T cells (Zingonicompared to non-MV-infected YAC-CD46 mice at 6 days
postinfection, brains of YAC-CD46 MV-infected mice et al., 1998), or MIG, which is induced by IL-12, were
also detected in brains of YAC-CD46 mice inoculatedhad a 6-fold enhanced expression of IL-12 (p40), an 11-
fold enhancement of LT-b, and a 17-fold enhancement with MV. In contrast, chemokines, such as EOTXN,
which attracts eosinophils (Rolling, 1997), LTN, andof TNFa. There was also a 3-fold increase in IL-1a, 7-fold
increase of IL-1b, and 2-fold increase of both IL-1r and MIP-2 were not.
TNFb. Continued enhanced elevation of TNFa, LT-b,
and IL-12 was noted at 10 days post±MV infection. By
contrast, IFNg and IL-10 were not elevated in MV- MV Spreads Rapidly throughout the CNS
via Axonal Transportinfected mice. Several of these cytokinea (i.e., TNFa and
IL-1) have been associated with apoptosis (Ashkenazi Initial studies with polyclonal SSPE antibody docu-
mented the rapid and efficient spread of MV antigensand Dixit, 1998; Thornberry and Lazebnik, 1998). To de-
termine whether apoptosis accompanied MV infection, within axonal tracts throughout the CNS in seven out of
seven mice studied (Figure 6). Spread to distal sites wasthe in situ TUNEL assay was utilized. As a representative
sample in Figure 4P indicates, 50- to 100-fold more noted by the second to third day after infection with 103
pfu of MV. We then compared the identity of MV proteinsapoptotic cells in CD46 mice infected with MV than in
nontransgenic mice inoculated with MV or YAC-CD46 in neuronal cell bodies to that in axonal tracts using
monoclonal antibodies. Monoclonals specific for themice receiving a needle wound in their brains (Figure
Novel Small Animal Model to Dissect MV Pathogenesis
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Figure 6. Spread of MV throughout the CNS
Is Likely by Rapid Axonal Transport and via
MV RNP Complexes
(A) Polyclonal antibody (SSPE) to MV-stained
neuronal cell bodies in the cerebral cortex.
(B±F) MV N antigens expressed in axonal
tracts (B and C) leading to caudate nucleus
of the extra pyramidal system (D) and axonal
tracts in the corticospinal pyramidal tract (E
and F). Similar observations were noted in an
additional six MV-infected YAC-CD46 mice.
No staining of CNS was noted in control non-
YAC-CD46 mice inoculated with MV.
two viral glycoproteins HA and F can detect these anti- B lymphocytes and from F4/801 macrophages. These
observations were uniformly observed in four 6- togens on the membranes of infected cells, and those
against the N protein identify the antigen within the cell. 8-week-old YAC-CD46 mice inoculated i.v. with MV.
Lymphoid tissues or cells were obtained at day 3 or 7MV HA, F, and N were detected in neurons of YAC-CD46
mice examined 2, 5, and 7 days post±MV infection of after MV inoculation. In the next series of experiments,
we noted that MV suppressed the ability of YAC-CD46newborn mice (103 pfu, 105 pfu). In contrast, only the N
antigen was found within axonal tracts throughout the mice to mount both a cellular and humoral immune re-
sponse. As shown in Figure 7F, when MV was inoculatedCNS at comparable times. Electron microscopic exami-
nation did not reveal any budding virus in neurons but in YAC-CD46 mice primed 60 to 90 days earlier with
lymphocytic choriomeningitis virus (LCMV), splenic lym-indicated presence of nucleocapsids within axons (Fig-
ures 5A, 5B, 5E±5G). No evidence of formed virions was phocytes removed 3 days later were unable to mount
a MHC-restricted cytotoxic T lymphocyte response tonoted in axons. These findings supported the concept
that infectious virus was not being spread via the fluid LCMV-infected targets. In contrast, similarly harvested
lymphocytes from YAC-CD46 mice that were not in-phase but was likely transported as MV ribonucleopro-
tein complexes toward termini of neurites. fected with MV are able to kill LCMV-infected targets.
Killing was MHC restricted, as lysis by cytotoxic T cells
(CTLs) was only noted with LCMV-infected MHC classMV Infects and Can Be Isolated from Spleens
and PBL of Adult YAC-CD46 Mice and I matched but not with MHC class I mismatched target
cells. Suppression of cell-mediated CTL immune re-Suppresses Cell-Mediated and
Humoral Immune Responses sponse was also noted during primary virus infection.
All three YAC-CD46 H-2b mice receiving 1 3 105 pfu ofIn the last series of experiments, we analyzed MV infec-
tion of the immune system in adult YAC-CD46 mice. As vaccinia virus (VV) i.p. mounted a MHC-restricted (to H-2b
targets but not H-2q VV infected targets) virus-specificshown in Figure 7, the expression of CD46 molecules
on the surface of PBL was quantitatively similar in CTL response. Specific 51Cr release in a 5 hr assay being
30%, 23%, 10% at effector to target (E:T) ratios of 50:1,cells obtained from humans (A) and from YAC-CD46
transgenic mice (B); both were over 100-fold greater 25:1, and 12.5:1. In contrast, when 1 3 106 pfu of live
measles virus was given i.v. 3 days after VV priming,than amounts expressed by the b-actin (ba) promoter-
generated BC1 isoform of CD46 (C). Infectious MV was none of the mice (3/3) released .1% 51Cr even at the
highest 50:1 E:T ratio. When LCMV, instead of VV, wasrecovered from YAC-CD46 PBL or spleens (Figure 3;
Figures 7D and 7E) obtained 2 to 5 days after i.v. or i.p. used to generate a primary day 7 CTL response, similar
suppression of the cell-mediated immune response wasinjection when cocultivated on Vero cells, but not from
ba-CD46 transgenic mice. Infectious MV was recovered noted in some but not all inoculated mice, likely re-
flecting the known vigor of the LCMV CTL response.from purified populations (FACS) of CD81, CD41, and
Cell
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Figure 7. MV Induces Immunosuppression in
YAC-CD46 Transgenic Mice
PBL from humans (A) and from YAC-CD46
transgenic mice (B) expressed equivalent lev-
els of CD46 molecules on their surfaces. Such
expression was over 100-fold greater than
carried by PBL from b-actin (ba)-generated
transgenic mice (mouse ba-CD46 PBL, [C]).
(D) MV1 syncytia formed when PBL harvested
6 days after i.v. infection (104 pfu of MV) from
YAC-CD46 transgenic mice were coculti-
vated with Vero cells. Specificity for MV was
documented when syncytia was stained with
fluorochrome labeled monospecific antibody
to MV ([E]; see Experimental Procedures). (F)
Injection of MV into mice previously primed
to LCMV or into mice primed to SRBC (G)
prevents lymphocyte function in a LCMV-
specific CTL assay or generation of antibod-
ies to SRBC (numbers in bar graph indicate
number of mice making a response over the
total numbers in each group). See Experimen-
tal Procedures for details.
MV-infected YAC-CD46 mice were also unable to gen- promoter was replaced by that of ba or immediate early
genes of cytomegalovirus (CMV) (J. P. and M. B. A. O.,erate an antibody response to sheep red blood cells
(SRBC) (Figure 7). Thirteen out of 14 of such mice given unpublished observations; Baskar et al., 1996), CD46
expression was noted on PBL but only at low levels1 3 106 SRBC i.v. 5 days after virus infection failed to
mount antibody responses to the SRBC antigens 12 (Figure 7). Neither these cells nor lymphoid cells from
spleens and lymph nodes produced infectious MV indays later. In contrast, all six YAC-CD46 littermates
treated the same way except inoculated with vehicle vivo. By contrast, YAC-CD46 lymphoid cells had the
potential to preferentially express any or all isoformsgenerated antibody responses with a mean endpoint
sera titer dilution of 1/448 (range 1/256 to 1/1024). of CD46 and possessed CD46 levels 100- to 150-fold
greater than those expressed by cells from ba-CD46 or
CMV-CD46 mice (J. P. and M. B. A. O., unpublishedDiscussion
observations). PBL from YAC-CD46 mice and humans
expressed levels of CD46 molecules at comparably highIn this paper, we describe a transgenic mouse model
that reproduces many of the cardinal manifestations of levels (Figure 7). This coincided with efficient MV infec-
tion of YAC-CD46 lymphoid cells and production of in-MV infection. Criteria for virus-induced suppression of
the immune response and of CNS disease with spread fectious progeny from lymphocytes and macrophages
as MV does in humans (McChesney and Oldstone, 1989;of virus throughout the nervous system were met. Virus
replicated in both the immune system and CNS with Griffin and Bellini, 1996). Consistent with our findings
that low or no CD46 expression (i.e., ba-CD46 and CMV-recovery of infectious progeny.
Success in preparing this model required a high level CD46 transgenic mice) does not support MV replication
in vivo, others were unable to generate a CD46 animalof MV receptor expression on neurons and on cells of
the immune system. This was achieved by inserting the model of MV infection in vivo using various cDNAs of
CD46 (Horvat et al., 1997; Thorley et al., 1997). Suchfull-length genomic copy of CD46 into fertilized eggs to
allow expression of its four major isoforms. As a conse- cDNA constructs lack introns and regulatory sequences
that likely are beneficial for transgene expression. Aquence, formidable levels of CD46 proteins appeared
on the surfaces of neurons, lymphocytes, macrophages, direct correlation between levels of transgene expres-
sion and the production of disease has been describedand dendritic cells often at amounts comparable to
those naturally occurring in humans. When transgenic for other systems (Games et al., 1995; Rockenstein et
al., 1995). Recently, Mrkic et al. (1998) and Blixenkrone-mice expressed only the BC1 isoform in neurons, under
transcriptional regulation of the NSE promoter (Rall et Moller et al. (1998) utilized a YAC strategy to express
CD46 as was done here. However, in these other modelsal., 1997), 10- to 20-fold fewer CD46 molecules appeared
on neurons than when the endogenous CD46 gene was either lack of MV specificity (Mrkic et al., 1998), absent
or minimal to modest virus replication in and failure toused. The consequence for the infectious process was
that although MV replicated in neurons of NSE-CD46 recovery virus from the immune system (Mrkic et al.,
1998), lower CD46 expression levels, or need to damagetransgenic mice, the kinetics and spread of virus were
more restricted than in YAC-CD46 mice. the hosts interferon system (Blixenkrone-Moller et al.,
1998) for MV replication was noted. The explanation forAs expected, the transcriptional regulation of CD46
BC1 by NSE yielded mice that failed to express CD46 differences between CD46 genome models of others
and ours is not totally clear but may relate to the qualityon cells of the immune system (Rall et al., 1997), and
such cells were resistant to MV infection. When the NSE and quantity of YAC-CD46 sequences introduced into
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fertilized eggs or site(s) of DNA integration. In our YAC- from MV infection may be related to the effect of cyto-
kine(s) on immature neurons (Trgovcich et al., 1997; Ta-CD46 model, the ability to infect mice correlated directly
naka et al., 1998) and the susceptibility of neurons inwith the presence and expression levels of CD46 (see
newborns to apoptosis (Trgovcich et al., 1997; TanakaFigures 1, 3, 4, and 7). Further, all seven mouse strains
et al., 1998; Griffin and Hardwick, 1999), CNS toxinstested (FVB/N, SWR/J, C3H, BALB/c, C57BL/6, PL/J,
(Eastman et al., 1994), and/or lack of protection becauseand SJL/J) were susceptible to MV infection when they
of immaturity of the newborn immune system (Mosier,expressed CD46 molecules. This universal susceptibility
1974). In our model, MV replication in neurons of new-of multiple mouse strains contrasts to the selective sus-
born mice caused an acute CNS disease with deathceptibility of primarily the C3H (H-2k) strain reported for
within 3 weeks. By contrast, challenge of adults withmouse brain passaged MV (Liebert and Finke, 1995).
MV, while resulting in neuronal infection failed to pro-Analysis of the CNS infection in YAC-CD46 mice indi-
duce acute illness or death. Recently, using Rag2 knock-cated that MV replicated primarily in neurons and spread
out 3 NSE-CD46 transgenic mice, Lawrence et al. (1999)throughout the neural axis along axons likely by fast
noted that abolition of the CD4/CD8 T cell responseaxonal transport. Abundant documentation was ob-
enhanced the adults' susceptibility, resulting in a clinicaltained for MV transcription, translation, and recovery of
and pathologic picture similar to MV infection in theinfectious virus. This was supported by electron micros-
newborn. These results are consistent with the interpre-copy showing copious accumulation of MV nucleocap-
tation that the immune response protected adult micesids in neuronal cell bodies without detection of any
but not newborns against the spread of MV infection
budding virus. MV could be rescued from infected brains
within the CNS, although other factors such as varying
upon cocultivation with Vero cells. These observations susceptibilities of neurons during development and
of abundant nucleocapsid formation, absence of bud- aging might be involved in CNS pathogenesis (Johnson
ding, and requirement for cocultivation to isolate infec- et al., 1972; Trgovcich et al., 1997; Tanaka et al., 1998;
tious virus parallel the observations made with persis- Griffin and Hardwick, 1999). Thus, the acute CNS dis-
tent MV infection in brains of patients with SSPE (ter ease in newborns infected with MV may be pharmaco-
Meulen et al., 1983; Griffin and Bellini, 1996) and provide logically mediated and treatable with reagents that block
the opportunity to dissect the molecular parameters of the apoptosis-promoting cytokines. Alternatively, dur-
this human disease in our murine model. In preliminary ing MV infection, enzymes such as the double-stranded
studies, intranasal route of MV infection also allowed RNA adenosine deaminase may be induced by cyto-
spread and replication of MV. kines (Patterson et al., 1995), and this enzyme aberrantly
Two days after infection, MV clearly spread to neurons edits glutamate receptors so as to interfere with Ca21
at multiple sites throughout the brain, including into cells flux, thereby causing neuronal dysfunction and death
of the cerebellum, hippocampus, striatum, and cerebral (Lomeli et al., 1994). These possibilities are now being
cortex. MV nucleocapsids were noted in the prominent explored.
axonal tracts, including those connecting the extrapyra- In our YAC-CD46 transgenic mice, MV can infect cells
midal and cerebellar systems and the cortico-spinal py- of the immune system, as evident by presence of viral
ramidal tract (Figures 5 and 6). Immunochemical analy- gene products in CD41 and CD81 T lymphocytes, B
lymphocytes, in the T-enriched area of the spleen lymphsis indicated MV HA and F in the neuronal soma but
nodes, Peyer's patches, and circulating PBL and recov-absent from axons; this, in concert with the absence of
ery of infectious MV by coculture of spleen lymphoidvirions in axons, lack of virus budding, and our inability
cells, CD81 and CD41 T cells, B cells, PBL, and macro-to recover free virus from brain tissue suggested that
phages on susceptible Vero cells (Figures 3 and 7). Adultinfection likely spread via an infectious ribonucleopro-
YAC-CD46 mice, which ordinarily mount an effectivetein complex. This conclusion was strengthened by ob-
cell-mediated CTL response after challenge with LCMVserving MV nucleocapsid complexes within axons (Fig-
or VV, or a robust antibody response after immunizationure 5). Others using in vitro assays have shown infectivity
to SRBC, failed to do so when infected with MV, thusof MV RNP complexes for cells (Rozenblatt et al., 1979;
imitating suppression by MV noted in humans (McChes-Griffin and Bellini, 1996).
ney and Oldstone, 1989; Griffin and Bellini, 1996). Fur-An abundance of CD41 T lymphocytes along with
ther, in preliminary studies (Slifka et al., unpublishedCD81 T cells infiltrated into the brain parenchyma. Inter-
observations), MV-infected transgenic mice replicated
estingly, the enhanced frequency of CD41 T over that
6-fold more Listeria monocytogenes in their spleens
of CD81 T cells in brain lesions mirrors in vivo as well than noninfected transgenic mice, suggesting enhanced
as in vitro observations of human CTL in MV infection susceptibility to opportunistic infections. The fact that
(Long and Jacobson, 1989), suggesting that MV may CD81, CD41, and B lymphocytes; macrophages; and
block the MHC class I antigen presentation pathway dendritic cells from YAC-CD46 mice expressed high lev-
(Oldstone, 1997). In vitro, effects of MV on antigen-pre- els of CD46 molecules on their surfaces and can be
senting dendritic cells have been noted (Fugier-Vivier et infected with MV in vitro (Figure 2) in association with
al., 1997; Grosjean et al., 1997; Schnorr et al., 1997). The findings that CD81, CD41 T cells, and macrophages are
lymphocyte infiltration we describe was associated with infected in vivo indicates this model's usefulness for
astrocytosis, proliferation of microglia, elevation of se- adoptive transfers to complement deficiencies in mice
lected Th1 cytokines, and chemokines. The chemokines after selective knockout of immune system compo-
expressed (Rantes, MIPa and b, MCP-1, IP-10, and nents. Thus, this model presents an opportunity to de-
TCA-3) are those known to attract or emanate from T cells fine in vivo the mechanism of immune system suppres-
sion by MV and to develop strategies for overcoming(Rolling, 1997; Zingoni et al., 1998). Mortality resulting
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a MV nucleocapsid (N) probe was prepared by random primer label-that defect. A further application is testing of new MV
ing of a 1.7 kb DNA fragment from the MV N gene (plasmid peNI,vaccines that provide immunity without immunosup-
kindly provided by Dr. Martin Billeter, Zurich, Switzerland). Blotspression, a failing of the currently utilized vaccine (Mar-
were probed with a random-primed, 32P-labeled DNA probe for either
kowitz and Katz, 1994; Griffin and Bellini, 1996). Lastly, CD46 or MV N RNA. RNA loading in each sample was quantified by
infection of the YAC-CD46 transgenic model by MVs in hybridization of the same blots with a 32P-labeled cDNA probe spe-
cific for cyclophilin. To detect CD46 and MV RNA in whole bodywhich individual viral genes have been deleted by re-
sections, mice of various ages were sacrificed, placed in carboxy-verse genetics (Radecke et al., 1995) may provide a way
methlycellulose (CME), and frozen in a dry ice and alcohol bath.to ascertain the role of individual MV genes in determin-
Sections (20 to 40 mm) were obtained on 3M tape and either airing the parameters involved in the CNS disease and
dried and directly hybridized with a 32P riboprobe to detect RNA or
immunosuppression. transferred to a nylon membrane for detection of protein (Oldstone
et al., 1986; Lipkin et al., 1989). Riboprobes for MV N and CD46
were prepared and labeled with 32P. Briefly, a 289 bp CD46 moleculeExperimental Procedures
was obtained by digestion of pBSC CD46 (containing BC1 isoform)
with BsaI and transcribed in vitro in the presence of 32P UTP andMice and Virus Used
T7 polymerase. The resulting 289 nucleotide sequence constitutingGeneration of the YAC-CD46 transgenic mouse line 2 and NSE-
the riboprobe was purified and used in hybridization.CD46 mouse line 52 has been described (Yannoutsos et al., 1996;
To detect MV N gene, a 650 bp fragment of the gene was generatedRall et al., 1997). Progeny YAC-CD46 mice were crossed with mice
by PCR and inserted into a pSP71. Primer pairs A: 59-GCTGAATTCAATof the FVB/N, SWR/J, BALB/c, C3H, PLJ, and SJL/J backgrounds
TAACCCTCACTAAAGGG-39 and B: 59-CGGCTCGAGGGGCCGTAACCfor a minimum of two generations. NSE-CD46 and YAC-CD46
GCCTTTGCT-39 corresponding to the T3 region of the pBluescripttransgenics were bred for seven generations onto C57BL/6 back-
KS (59 end) and an internal MV NC gene sequence (39 end), respec-grounds. To generate mice expressing the human CD46 BC1 isoform
tively, were used to amplify the 59 end of the MV NC gene by PCRcDNA under control of the human ba promoter, the human ba and
using peNI as the template. This PCR fragment was digested withCD46 sequences were isolated from the plasmid pK523 (kindly pro-
EcoRI and XhoI and subcloned into the same sites in the pSP71vided by John Atkinson, Washington University School of Medicine,
vector (Promega) in a 39 to 59 orientation with respect to the T7St. Louis, MO), digested with PvuI, and partially digested with CspI
promoter. The template was linearized with EcoRI for generation ofto generate a 9.5 kb fragment. The fragment was cloned into the
the antisense MV N riboprobe using T7 RNA polymerase. For detec-vector pBC SK1 (Stratagene, La Jolla, CA) in which a CspI linker
tion of CD46 protein in whole-animal sections, we used anti-CD46had been introduced into the XbaI-XhoI cloning sites. After digestion
monoclonal antibody E4.3 or rabbit polyclonal antibody to CD46with XbaI and PvuL, the 9.5 kb fragment containing the ba promoter
(Manchester et al., 1994) followed by 125I Staph A, and for MV proteinssequences, BC1 cDNA, and SV40 transcription terminator was iso-
polyclonal SSPE antibody followed by 125I Staph A or fluorochromelated and injected into fertilized (C57BL/6 3 C3H/HeJ) F1 eggs. The
probes (Oldstone et al., 1986; Lipkin et al., 1989; Manchester et al.,resulting offspring were crossed with C57BL/6 or C3H/HeJ mice.
1994; Rall et al., 1997).Founder animals and subsequent breeders were housed in the
A riboprobe to detect MV N using digoxigenin was also used onmouse hepatitis virus, pathogen-free breeding colony of The Scripps
free-floating, vibratome-cut sections (40 mm thick) of mouse brainsResearch Institute (La Jolla, CA).
fixed in 4% paraformaldehyde or sorted lymphocytes as describedThe primary virus used was MV Edmonston strain, whose origin,
(Tishon et al., 1988; Holz et al., 1996).biological properties, and quantitation by plaquing on Vero cells are
detailed elsewhere (McChesney and Oldstone, 1989; Manchester
et al., 1994; Rall et al., 1997). Inocula were 103, 104, or 105 pfu of MV Immunocytochemical and Histological Assays
for YAC-CD46 and NSE-CD46 mice and 106 pfu of MV for ba-CD46 Immunocytochemistry was also done on tissues either frozen in
mice. MV was inoculated either intracerebrally (i.c.), intraperitoneally CME cut in 8 to 10 mM sections by cryomicrotome, 40 to 75 mM
(i.p.), or intravenously (i.v.). sections made with a Leica 10002 Vibratome, or FACS sorted cells.
MV was recovered from brain and spleen by cocultivation on Vero Most often, sections or cells were placed on either sialin-coated
cells. Briefly, a suspension of brain tissue was placed on a ficoll- superfrost-plus slides or round-bottomed 96-well plates and fixed
hypaque gradient as described (Rall et al., 1997) and cocultivated for 1 min in 1% paraformaldehyde, washed, and stained with mono-
with Vero cells (Manchester et al., 1994; Rall et al., 1997). Splenic clonal antibodies to MV HA, MV F, MV N (obtained through WHO
tissue was passed through a 100 mm nylon mesh and RBC removed Reference Center, E. Norrby, Sweden, and R. Cattaneo, Zurich),
by treatment with NH4Cl (Oldstone et al., 1991; von Herrath et al., CD46, MBP, NSE, NF, F4/80, MAC-1, CD4, CD8, B220, or polyclonal
1994). Resultant lymphoid cells are washed and cocultivated on antibody to MV (SSPE sera) or GFAP as described (Manchester et
Vero cells. Cultures formed syncytia, and identity of MV was deter- al., 1994; von Herrath et al., 1994; Evans et al., 1996; Rall et al.,
mined on infected cells by immunofluorescence using a specific 1997; Horwitz et al., 1999). Secondary antibody was biotinylated or
antibody to MV (Manchester et al., 1994; Rall et al., 1997). Amounts fluoresceinated goat anti-rat IgG, rat anti-mouse IgG, or goat anti-
of infectious virus made were determined by plaquing log dilutions human IgG, followed by avidin-POD conjugate (for biotinylated anti-
of supernatant fluids on Vero cells. Technique for separation of body) from Boehringer-Mannheim (La Jolla, CA). With biotinylated
CD41, CD81, B lymphocyte, and macrophage populations using antibodies, color reactions developed with diaminobenzidine in the
fluorochrome-labeled monoclonal antibodies and FACS has been presence of hydrogen peroxide as described (Evans et al., 1996;
published (Tishon et al., 1988; Homann et al., 1998). Horwitz et al., 1999). Specificity of reagents and controls used have
Characterization, use, and quantitation of LCMV and VV have been been published (von Herrath et al., 1994; Evans et al., 1996; Rall et
noted earlier (Oldstone et al., 1991). al., 1997).
Suspensions of living cells were phenotyped by FACS analysis
for expression of CD46 and MV HA, F, or N as described (McChesneyDNA, RNA, and Protein Analysis
and Oldstone, 1989; Oldstone et al., 1991; Manchester et al., 1994;The transgene's presence was identified by Southern blot analysis
Rall et al., 1997; Homann et al., 1998).(Rall et al., 1997). CD46 and MV RNA were detected by Northern
Histological analysis was done on tissues fixed in zinc formalinblot analysis using standard procedures. Tissues were removed,
(10%), paraffin embedded, sectioned, and stained with hematoxylinsnap frozen in liquid nitrogen, and used as the source of RNA or
and eosin.protein (Oldstone et al., 1991; Manchester, et al., 1994; Rall et al.,
1997). Total RNA (10 mg/sample) was run on a 1% formaldehyde
gel and transferred to Nytran membranes (Micron Separations, Inc., Electron Microscopy
Infected mouse brain was divided sagitally, and one-half was pro-Westboro, MA). For detection of CD46 mRNA, a CD46 probe was
prepared by random-primer labeling of a 1.6 kb DNA fragment from cessed for examination by light microscopic immunocytology to
localize sites of MV expression. The other half was fixed in 2%the CD46 gene (Liszewski et al., 1991). For detection of MV mRNA,
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glutaraldehyde in phosphate-buffered saline, postfixed in 1% OSO4, Eastman, C.L., Urbanska, E., Love, A., Kristensson, K., and
Schwarcz, R. (1994). Increased brain quinolinic acid production indehydrated, and embedded in Eri 812 resin. Thin sections were
stained with uranyl and lead salts and examined in a JOEL 100 CX mice infected with a hamster neurotropic measles virus. Exp. Neurol.
125, 119±124.electron microscope at 80 KV.
Evans, C.F., Horwitz, M.S., Hobbs, M.V., and Oldstone, M.B.A.
Detection and Quantitation of Cytokine and Chemokine (1996). Viral infection of transgenic mice expressing a viral protein
RNAs by RPA in oligodendrocytes leads to chronic central nervous system autoim-
Cytokine mRNAs were measured using the RiboQuant RPA assay mune disease. J. Exp. Med. 184, 2371±2384.
system (Pharmingen, La Jolla, CA) as recommended by the manu- Fugier-Vivier, I., Servet-Delprat, C., Rivailler, P., Rissoan, M.C., Liu,
facturer as described (Evans et al., 1996). Either total brain RNA (20 Y.J., and Rabourdin-Combe, C. (1997). Measles virus suppresses
mg/sample) or poly(A)-enriched RNA (5 mg) was used, and bands cell-mediated immunity by interfering with the survival and functions
corresponding to protected cytokine or chemokine mRNAs were of dendritic and T cells. J. Exp. Med. 186, 813±823.
quantitated on a Molecular Dynamics PhotoImager using the pro-
Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette,gram ImageQuant and normalized to the amounts of L32 and GAPDH
P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie,standards in each lane.
F., et al. (1995). Alzheimer-type neuropathology in transgenic mice
overexpressing V717F b-amyloid precursor protein. Nature 373,CTL Assay
523±527.The functional activity of primary (day 7) and immune (day 45±60)
Griffin, D.E., and Bellini, W.J. (1996). Measles virus. In Fields Virology,splenic lymphocytes was determined by in vitro 51Cr release assay
B. Fields et al., eds. (Philadelphia: Lippincott-Raven), pp. 1267±1312.(Oldstone et al., 1991; von Herrath et al., 1994; Evans et al., 1996).
All samples were run in triplicate, and CTL to LCMV were raised by Griffin, D.E., and Hardwick, J.M. (1999). Virus infections and the
inoculating either FVB/N, BALB/c, or C57BL/6 mice (6- to 8-weeks- death of neurons. Trends Microbiol. 7, 155±160.
old) i.p. with 1 3 105 pfu of LCMV ARM 53b. After 60 to 90 days, Grosjean, I., Caux, C., Bella, C., Berger, I., Wild, F., Banchereau, J.,
selected mice were given 1 to 2 3 105 pfu of MV i.v. Four days later, and Kaiserlian, D. (1997). Measles virus infects human dendritic cells
their spleens were harvested, and the lymphocytes recovered were and blocks their allostimulatory properties for CD41 T cells. J. Exp.
cultured for 4 days by a standard protocol (Oldstone et al., 1991; Med. 186, 801±812.
von Herrath et al., 1994). Lymphocytes were then tested against
Holz, A., Schaeren-Wiemers, N., Schaefer, C., Pott, U., Colello, R.,MHC-restricted FVB/N 51Cr-labeled fibroblasts infected 2 days ear-
and Schwab, M. (1996). Molecular and developmental characteriza-lier with LCMV ARM or MHC mismatched but similar infected targets.
tion of novel cDNAs of the myelin associated/oligodendrocyte basic
protein. J. Neurosci. 16, 467±477.Sheep Red Blood Cell Immunization and Assay
Homann, D., Tishon, A., Berger, D.P., Weigle, W.O., von Herrath,Preliminary studies indicated that YAC-CD46 mice failed to make
M.G., and Oldstone, M.B.A. (1998). Evidence for an underlying CD4antibodies to SRBC when inoculated with 1 3 105 SRBC but did
helper and CD8 T cell defect in B cell-deficient mice: failure to clearwhen immunized with 5 3 105 or 1 3 106 SRBC given i.p. Low-
persistent virus infection after adoptive immunotherapy with virus-antibody titers occurred in some mice 5 days, reaching maximal
specific memory cells from mMT/mMT mice. J. Virol. 72, 9208±9216.titers in all mice at 12 days after inoculation. Two- to three-month-
old FVB/N YAC-CD46 mice were given 1 3 106 SRBC i.p., and 5 Horvat, B., Rivailler, P., Varior-Krishnan, G., Cardoso, A., Gerlier,
D., and Rabourdin-Combe, C. (1997). Transgenic mice expressingdays later one group received 1.2 3 106 pfu of MV i.v. or similar
inoculum of MV-free vehicle. Twelve days later individual mice were human measles virus (MV) receptor CD46 provide cells exhibiting
different permissivities to MV infection. J. Virol. 70, 6673±6681.bled and antibodies to SRBC titered as described (Oldstone et al.,
1973). Prior to initiation of SRBC immunization, all mice were bled Horwitz, M.S., Evans, C.F., Klier, F.G., and Oldstone, M.B.A. (1999).
and individual sera shown not to hemagglutinate SRBC at 1:8 di- Detailed in vivo analysis of interferon-g induced MHC expression in
lution. the CNS: astrocytes fail to express MHC class I and II molecules.
Lab. Invest. 79, 235±242.
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